GPT and metabolic dysfunction-associated steatohepatitis: NASH patients receiving OCA treatment showed improvements in ALT (MD: −19.48, 95% CI: −24.39 to 14.58; P < .05) and AST (MD: −9.22, 95% CI: −12.70 to 5.74; P < .05) compared to NASH patients who received a placebo.